

USSN 09/554,533
Atty Docket No. 238/086US

REMARKS

Claims 1-54 were pending. New claims 55-75 are added. Support for the new claims is found throughout the specification at, *inter alia*, the original claims. Thus, it is believed that no new matter has been added. Claims 1-54 are canceled herewith without prejudice. Claims 55-75 are pending. No claim is allowed.

Summary of Examiner's Interview

Applicants are very grateful for the time and guidance provided by Examiner Ungar in the Examiner's interview of April 19, 2006. In brief, the undersigned, Dr. Jim Butler, and Examiner Ungar discussed the Restriction Requirement dated October 3, 2005. We agreed that new claims would be submitted that further clarify the genus of peptides for examination. Examiner Ungar also indicated the case would likely be transferred to a new art unit because of the claimed subject matter, and she would support further restriction (if necessary) and examination of the new claims. Examiner Ungar's advice was thoughtful and helpful, and Applicants thank her for her exceptional efforts in this case.

New claims

In view of the interview summarized above, Applicants submit herein new claims 55-75. It is believed that these claims further clarify the genus of peptides (and related methods of use) for examination.

Applicants respectfully request examination of the pending claims on the merits.

USSN 09/554,533
Atty Docket No. 238/086US


CONCLUSION

No additional fees are believed due for this submission other than those provided herewith. However, if any additional fee(s) is due, the Commissioner is hereby authorized to charge payment of any fees associated with this communication, to Applicant's Deposit Account No. 010535. Additionally, the Commissioner is hereby authorized to charge payment or credit overpayment of any fees during the pendency of this application to Applicant's Deposit Account No. 010535.

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.

Dated: April 27, 2006

By:



Laurie L. Hill, Ph.D.

Registration No. 51, 804

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Telephone: 858.552.2200
Facsimile: 858.552.1936